Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sionna Therapeutics Inc (SION)

Sionna Therapeutics Inc (SION)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,879,567
  • Shares Outstanding, K 44,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,270 K
  • EBIT $ -89 M
  • EBITDA $ -91 M
  • 60-Month Beta 3.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.51

Options Overview Details

View History
  • Implied Volatility 95.79% (-2.92%)
  • Historical Volatility 63.69%
  • IV Percentile 59%
  • IV Rank 61.10%
  • IV High 109.32% on 03/20/26
  • IV Low 74.54% on 03/18/26
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 110.67
  • Today's Volume 335
  • Volume Avg (30-Day) 52
  • Put/Call OI Ratio 13.68
  • Today's Open Interest 543
  • Open Int (30-Day) 111
  • Expected Range 43.30 to 43.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.54
  • Number of Estimates 2
  • High Estimate $-0.47
  • Low Estimate $-0.60
  • Prior Year $-0.62
  • Growth Rate Est. (year over year) +12.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.20 +30.42%
on 03/19/26
44.71 -3.15%
on 04/14/26
+5.98 (+16.02%)
since 03/13/26
3-Month
32.46 +33.39%
on 02/05/26
44.99 -3.76%
on 02/02/26
+2.12 (+5.15%)
since 01/14/26
52-Week
8.60 +403.49%
on 04/15/25
45.00 -3.78%
on 12/29/25
+34.39 (+385.97%)
since 04/14/25

Most Recent Stories

More News
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium

WALTHAM, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 43.30 (+3.66%)
Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated...

SION : 43.30 (+3.66%)
Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences

WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 43.30 (+3.66%)
Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 43.30 (+3.66%)
Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 43.30 (+3.66%)
Stocks Retreat as Bond Yields Rise

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down by -0.53%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down by -0.90%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down by -0.36%....

MSTR : 137.41 (+3.82%)
MPC : 223.93 (-0.60%)
GLXY : 23.72 (+5.42%)
LVS : 55.52 (+1.24%)
WYNN : 105.59 (+2.45%)
$IUXX : 25,842.00 (+1.81%)
COIN : 184.41 (+5.66%)
ZNM26 : 111-170 (unch)
SHOP : 117.64 (+2.32%)
SION : 43.30 (+3.66%)
ESM26 : 7,005.50 (+0.01%)
FANG : 186.51 (-1.37%)
Stocks Fall as Rising Bond Yields Spark Risk-Off Sentiment

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.28%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.29%. December E-mini...

MSTR : 137.41 (+3.82%)
MPC : 223.93 (-0.60%)
CVX : 187.02 (-2.48%)
GLXY : 23.72 (+5.42%)
LVS : 55.52 (+1.24%)
WYNN : 105.59 (+2.45%)
$IUXX : 25,842.00 (+1.81%)
COIN : 184.41 (+5.66%)
ZNM26 : 111-170 (unch)
SHOP : 117.64 (+2.32%)
OXY : 55.38 (-4.62%)
SION : 43.30 (+3.66%)
Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down by -0.59%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down by -0.40%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down by -0.97%. December E-mini...

MSTR : 137.41 (+3.82%)
MPC : 223.93 (-0.60%)
CVX : 187.02 (-2.48%)
GLXY : 23.72 (+5.42%)
LVS : 55.52 (+1.24%)
WYNN : 105.59 (+2.45%)
$IUXX : 25,842.00 (+1.81%)
COIN : 184.41 (+5.66%)
ZNM26 : 111-170 (unch)
SHOP : 117.64 (+2.32%)
OXY : 55.38 (-4.62%)
SION : 43.30 (+3.66%)
Sionna Therapeutics to Participate in Upcoming December Investor Conferences

WALTHAM, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for...

SION : 43.30 (+3.66%)
Sionna Therapeutics Reports Third Quarter 2025 Financial Results

Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis Successfully completed drug-drug interaction...

SION : 43.30 (+3.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sionna Therapeutics Inc. is a clinical-stage biopharmaceutical company by developing novel medicines that normalize the function of the CFTR protein. Sionna Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 48.56
2nd Resistance Point 46.64
1st Resistance Point 44.97
Last Price 43.30
1st Support Level 41.37
2nd Support Level 39.45
3rd Support Level 37.78

See More

52-Week High 45.00
Last Price 43.30
Fibonacci 61.8% 31.10
Fibonacci 50% 26.80
Fibonacci 38.2% 22.50
52-Week Low 8.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.